Michael McMann, MD
Ophthalmology · Ewa Beach, HINPI 1215941190
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,105 of the $4,332 with a category attached, or 71.7%. 17 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 38.7% of the total. Reporting peaked in 2019 at $1,984 and has fallen 79.4% since, to $409 in 2025.
Across 76 payments — averaging $57.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$663
- Amgen$364
- Aerie Pharmaceuticals, Inc.$272
- Dompe US, Inc.$243
- Sun Pharmaceutical Industries Inc.$235
- plus $879 from 11 others
What the payments were for
- Travel & lodging$1,22628%
- Food & beverage$3,10572%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 5 | $1,676 |
| Alcon | 15 | $663 |
| Amgen(2 entities) | 8 | $364 |
| Aerie Pharmaceuticals, Inc. | 10 | $272 |
| Dompe US, Inc. | 2 | $243 |
| Sun Pharmaceutical Industries Inc. | 8 | $235 |
| Bausch & Lomb Americas Inc. | 4 | $181 |
| ANI Pharmaceuticals, Inc. | 2 | $155 |
| AbbVie(2 entities) | 6 | $142 |
| Mallinckrodt Hospital Products Inc. | 2 | $138 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $117 |
| Sight Sciences, Inc. | 2 | $41 |
| Kala Pharmaceuticals, Inc. | 2 | $37 |
| Harrow Eye, LLC | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Beaver-visitec International, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,546
- Tecnis 3-piece IOL$1,546
- Tecnis Symphony IOL$1,546
- Tecnis Symphony Toric IOL$1,546
- Clareon$282
- Oxervate$243
- Hydrus Microstent$147
- TEPEZZA$130
- enVista MX60 IOL$125
- PURIFIED CORTROPHIN GEL$125
- Rhopressa$120
- Rocklatan$120
- ACTHAR$118
How this compares
$4,332 in reported general payments places this provider in the 60th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $16,786 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $10,498 |
| ProlensaBromfenac Sodium | 15 | $6,392 |
| Prednisolone Acetate | 64 | $4,550 |
| MoxifloxacinMoxifloxacin Hcl | 73 | $3,622 |
| Bromfenac Sodium | 18 | $3,379 |
| Latanoprost | 246 | $3,242 |
| Brimonidine Tartrate | 47 | $2,947 |
| Loteprednol Etabonate | 12 | $1,510 |
| Difluprednate | 12 | $1,155 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $1,021 |
| Timolol Maleate | 68 | $859 |
| Diclofenac Sodium | 27 | $476 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 22 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $142 | $16,78615 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $272 | $10,49812 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $117 | $7,90127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Ewa Beach
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Gregg KokameAiea$73K
- Rupa WongHonolulu$72K
- William WongAiea$40K
- Luis OmphroyAiea$25K
- Sarah ReadAiea$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.